Salvage therapy in refractory acute myeloid leukemia: Prediction of outcome based on analysis of prognostic factors

Leukemia Research

Volumn 27, Issue 3, 2003, Pages 205-214

  Tavernier, Emmanuelle ^a   Le, Quoc Hung ^a   Elhamri, Mohamed ^a   Thomas, Xavier ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Acute myeloid leukemia; Prognosis; Resistance; Salvage chemotherapy

Indexed keywords

AMSACRINE; CD34 ANTIGEN; CYTARABINE; DAUNORUBICIN; HLA ANTIGEN; LACTATE DEHYDROGENASE; MITOXANTRONE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; APLASIA; ARTICLE; BLEEDING; BLOOD CELL COUNT; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DEATH; DIARRHEA; DONOR; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HEART FAILURE; HUMAN; INFECTION; KARYOTYPE; LEUKEMIA CELL; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIVARIATE ANALYSIS; NAUSEA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; SALVAGE THERAPY; SIBLING; SIDE EFFECT; SKIN TOXICITY; SURVIVAL TIME; THROMBOCYTE COUNT; TREATMENT OUTCOME; WEIGHT REDUCTION;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AMSACRINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELL COUNT; CYTARABINE; DRUG EVALUATION; FEMALE; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037353342     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00089-9     Document Type: Article

References (28)

1. Schiller G., Gajewski J., Nimer S., Territo M., Ho W., Lee M.et al. A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukemia. Br. J. Haematol. 81:1992;170-177.
2. Mayer R.J., Davis R.B., Schiffer C.A., Berg D.T., Powell B.L., Schulman P.et al. For the Cancer and Leukemia Group B. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N. Engl. J. Med. 332:1994;217-223.
3. Te Boekhorst P., Löwenberg B., van Kapel J., Nooter K., Sonneveld P. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. Leukemia. 9:1995;1025-1031.
4. Cain B.F., Atwell G.J. The experimental antitumor properties of three congeners of the acridly methanesulphonanilide (AMSA) series. Eur. J. Cancer. 10:1974;539-549.
5. Legha S.S., Keating M.J., Zander A.R., McCredie K.B., Bodey G.P., Freireich E.J. 4′-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia. Ann. Int. Med. 93:1980;17-21.
6. Arlin Z.A., Sklaroff R.B., Gee T.S., Kempin S.J., Howard J., Clarkson B.D.et al. Phase I and II trial of 4′-(9-acridinylamino) methanesulfon-m-anisidide in patients with acute leukemia. Cancer Res. 40:1980;3304-3306.
7. Weiss R.B., Charles L.M. Jr., Macdonald J.S. m-AMSA: an exciting new drug in the National Cancer Institute Drug Development Program. Cancer Clin. Trials. 3:1980;203-209.
8. Hines J.D., Oken M.M., Mazza J.J., Keller A.M., Streeter R.R., Glick J.H. High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute non-lymphocytic leukemia. J. Clin. Oncol. 2:1984;451-458.
9. Arlin Z.A., Flomenberg N., Gee T.S., Kempin S.J., Dellaquila C., Mertelsmann R.et al. Treatment of acute leukemia in relapse with 4′-(9 acridinylamino)-methansulfon-m-anisidide (AMSA) in combination with cytosine and thioguanine. Cancer Clin. Trials. 4:1981;317-321.
10. Vogler WR, Stein R, Velez-Garcia E, et al. New approaches in the treatment of acute myeloblastic leukemia: results of recent Southeastern Study Group trials. In: Gale RP, editor. Acute myelogenous leukemia: progress and controversies. New York: Wiley, 1990. p. 303-12.
11. Berman E., Arlin Z.A., Gaynor J., Miller W., Gee T., Kempin S.J.et al. Comparative trial of cytarabine and thioguanine in combination with amsacrine and daunorubicin in patients with untreated acute non-lymphocytic leukemia: results of the L-16M protocol. Leukemia. 3:1989;115-121.
12. Archimbaud E., Thomas X., Michallet M., Jaubert J., Troncy J., Guyotat D.et al. Prospective genetically randomized comparison between intensive postinduction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia. J. Clin. Oncol. 12:1994;262-267.
13. Castaigne S., Archimbaud E., Bordessoule D., Fenaux P., Tilly H., de Revel T.et al. For the AML Study Group. Preliminary results of LAM 90 trial on adult acute myelogenous leukemia: Comparison of standard induction chemotherapy versus double or sequential induction chemotherapy. Br. J. Haematol. 93(Suppl. 2):1996;133.
14. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A.G., Gralnick H.R.et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann. Int. Med. 103:1985;626-629.
15. ISCN (International System for Human Cytogenetic Nomenclature). Guidelines for cancer cytogenetics. In: Mitelman F, editor. Supplement to an International System for Human Cytogenetic Nomenclature. Basel: Karger, 1991. p. 1-53.
16. Ellison R.R., Holland J.F., Weil M., Jacquillat C., Boiron M., Bernard J.et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood. 32:1968;507-523.
17. Preisler H.D. Failure of remission induction in acute myelocytic leukemia. Med. Pediatr. Oncol. 4:1978;275-276.
18. Harrell F.E. Jr., Lee K.L., Mark D.B. Multivariate prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 15:1996;361-387.
19. Jehn U., Heinemann V. Phase II-study for treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine. Anticancer Res. 13:1993;379-381.
20. Willemze R., Suciu S., Archimbaud E., Muus P., Stryckmans P., Louwagie E.A.et al. A randomized phase II study on the effects of 5-aza-2′-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). Leukemia. 11(Suppl. 1):1997;S24-S27.
21. Kahn S.B., Sklaroff R., Lebedda J., Conroy J.F., Bulova S., Brodsky I. 4′-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA) and 5-azacytidine (AZA) in the treatment of relapsed adult acute leukemia. Am. J. Clin. Oncol. 6:1983;493-502.
22. Letendre L., Hinemann V., Hoagland H.C., Kovach J.S. Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia. Med. Pediatr. Oncol. 13:1985;232-234.
23. Keating M.J., Gehan E.A., Smith T.L., Estey E.H., Walters R.S., Kantarjian H.M.et al. A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia. J. Clin. Oncol. 5:1987;710-721.
24. Arlin Z.A., Feldman E.J., Mittelman A., Ahmed T., Puccio C., Chun H.G.et al. Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia. Cancer. 68:1991;1198-1200.
25. Estey E.H., Keating M.J., Smith T.L., McCredie K.B., Legha S.S., Walters R.S.et al. Prediction of complete remission in patients with refractory acute leukemia treated with AMSA. J. Clin. Oncol. 12:1984;102-106.
26. Schiffer C.A., Lee E.J., Tomiyasu T., Wiernik P.H., Testa J.R. Prognostic impact of cytogenetic abnormalities in patients with de novo acute non-lymphocytic leukemia. Blood. 73:1989;263-270.
27. Keating M.J., Smith T.L., Kantarjian H., Cork A., Walters R., Trujillo J.M.et al. Cytogenetic pattern in acute myelogenous leukemia: a major reproductible determinant of outcome. Leukemia. 2:1988;403-412.
28. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G.et al. Goldstone A on behalf of the Medical Research Council Adult and Children's Leukaemia Working Parties. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood. 92:1998;2322-2333.